Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies.

Overview of attention for article published in Cancer Immunology Research, September 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

So far, Altmetric has seen 6 news stories from 5 outlets.

Recent findings suggest that a new drug The cancer drug, called NJH395, could stimulate the immune system to attack tumors from…

Recent findings suggest that a new drug The cancer drug, called NJH395, could stimulate the immune system to attack tumors from…

Recenti risultati suggeriscono che un nuovo farmaco antitumorale chiamato NJH395 può stimolare il sistema immunitario ad…

Recenti risultati suggeriscono che un nuovo farmaco antitumorale chiamato NJH395 può stimolare il sistema immunitario ad…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 2 additional news stories.